LU93029I2 - Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir - Google Patents

Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir Download PDF

Info

Publication number
LU93029I2
LU93029I2 LU93029C LU93029C LU93029I2 LU 93029 I2 LU93029 I2 LU 93029I2 LU 93029 C LU93029 C LU 93029C LU 93029 C LU93029 C LU 93029C LU 93029 I2 LU93029 I2 LU 93029I2
Authority
LU
Luxembourg
Prior art keywords
tenofovir
alfenamide
solvate
salt
alafenamide
Prior art date
Application number
LU93029C
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22821718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of LU93029I2 publication Critical patent/LU93029I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
LU93029C 2000-07-21 2016-04-14 Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir LU93029I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22002100P 2000-07-21 2000-07-21
PCT/US2001/023104 WO2002008241A2 (fr) 2000-07-21 2001-07-20 Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration

Publications (1)

Publication Number Publication Date
LU93029I2 true LU93029I2 (fr) 2016-06-14

Family

ID=22821718

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93029C LU93029I2 (fr) 2000-07-21 2016-04-14 Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir

Country Status (37)

Country Link
US (10) US20040018150A1 (fr)
EP (3) EP1301519B2 (fr)
JP (4) JP4651264B2 (fr)
KR (2) KR100767432B1 (fr)
CN (2) CN1291994C (fr)
AP (1) AP1466A (fr)
AU (3) AU8294101A (fr)
BE (1) BE2016C018I2 (fr)
BG (1) BG66037B1 (fr)
BR (1) BRPI0112646B8 (fr)
CA (3) CA2416757C (fr)
CY (2) CY2016008I2 (fr)
CZ (2) CZ304886B6 (fr)
DK (2) DK1301519T4 (fr)
EA (1) EA004926B1 (fr)
EE (1) EE05366B1 (fr)
ES (2) ES2627903T3 (fr)
FR (1) FR16C0013I2 (fr)
HK (1) HK1243711A1 (fr)
HR (2) HRP20160074B1 (fr)
HU (2) HU230960B1 (fr)
IL (1) IL153658A0 (fr)
IS (1) IS2985B (fr)
LT (2) LT2682397T (fr)
LU (1) LU93029I2 (fr)
MX (1) MXPA03000587A (fr)
NL (1) NL300803I2 (fr)
NO (6) NO336718B1 (fr)
NZ (3) NZ523438A (fr)
OA (1) OA12393A (fr)
PL (1) PL213214B1 (fr)
PT (2) PT1301519E (fr)
SI (2) SI1301519T1 (fr)
TR (1) TR200300055T2 (fr)
UA (1) UA75889C2 (fr)
WO (1) WO2002008241A2 (fr)
ZA (1) ZA200210271B (fr)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12393A (en) * 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
EA200400690A1 (ru) * 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
WO2003090691A2 (fr) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Technique et compositions permettant d'identifier des composes therapeutiques anti-vih
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
CA2523083C (fr) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
WO2004096285A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7273717B2 (en) * 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (fr) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
JP2007515495A (ja) * 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
ES2389602T3 (es) * 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH
AU2005209256B2 (en) * 2004-01-21 2010-11-18 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US7079156B1 (en) 2004-05-14 2006-07-18 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
CN1964967B (zh) 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
EP1865967A4 (fr) * 2005-04-08 2011-02-09 Chimerix Inc Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
CN100359315C (zh) * 2005-05-26 2008-01-02 林维宣 兽药残留能力验证样品及制备方法
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
DK2020996T3 (da) 2006-05-16 2012-02-27 Gilead Sciences Inc Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
WO2008007392A2 (fr) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Procédé amélioré destiné à préparer du ténofovir
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009038851A2 (fr) * 2007-06-26 2009-03-26 University Of Wyoming Research Corporation D/B/A Western Research Institute Systèmes de traitement et de prévention des eaux d'exhaure acides et des agents contaminants halogénés
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
AU2009206673B2 (en) * 2008-01-25 2015-04-23 Chimerix, Inc. Methods of treating viral infections
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
NZ588796A (en) 2008-04-25 2012-07-27 Cipla Ltd Crystalline form of tenofovir disoproxil and a process for its preparation
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010014134A1 (fr) * 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Composés et compositions pharmaceutiques pour le traitement d'infections virales
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
EP2376515A1 (fr) * 2008-12-23 2011-10-19 Pharmasset, Inc. Synthèse de nucléosides de type purine
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (fr) 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
EP3216789A1 (fr) 2010-02-12 2017-09-13 Chimerix, Inc. Procédés de traitement d'une infection virale
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8680071B2 (en) 2010-04-01 2014-03-25 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2797601A1 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Methodes de traitement d'infections retrovirales et regimes posologiques associes
WO2012012465A1 (fr) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Procédés de préparation de promédicaments au phosphoramidate pur au plan diastéréomère
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
BR112013014485B1 (pt) 2010-12-10 2021-03-30 Sigmapharm Laboratories, Llc Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
EP2691409B1 (fr) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
WO2012154698A2 (fr) * 2011-05-06 2012-11-15 Mckenna Charles E Procédé d'amélioration de l'activité antivirale de médicaments analogues de nucléotides
US8987437B2 (en) 2011-05-19 2015-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-HIV Agents
ES2608871T5 (es) * 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
AU2014271320B2 (en) * 2011-08-16 2017-02-23 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
AR088109A1 (es) * 2014-04-11 2014-05-07 Gilead Sciences Inc Metodo para preparar analogos nucleotidicos antivirales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013095684A1 (fr) 2011-12-22 2013-06-27 Geron Corporation Analogues de guanine en tant que substrats de télomérase et affecteurs de la longueur de télomères
WO2013115916A1 (fr) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Polythérapie comprenant le gs-7340 et le cobicistat destinée à être utilisée dans le traitement d'infections virales
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
GB201215696D0 (en) * 2012-09-03 2012-10-17 Ithemba Pharmaceuticals Pty Ltd A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
WO2014068265A1 (fr) * 2012-10-29 2014-05-08 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
CN102899327B (zh) * 2012-11-06 2014-06-11 清华大学深圳研究生院 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用
EP2920171B1 (fr) * 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
CN103848868B (zh) * 2012-12-04 2017-04-12 蚌埠丰原涂山制药有限公司 制备替诺福韦的方法
CN103848869B (zh) * 2012-12-04 2016-12-21 上海医药工业研究院 制备替诺福韦的方法
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN104072539B (zh) * 2013-03-25 2017-03-29 安徽贝克联合制药有限公司 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用
JP6262848B2 (ja) * 2013-05-21 2018-01-17 成都先導薬物開発有限公司 薬物標的の捕獲方法
US9676803B2 (en) 2013-06-07 2017-06-13 Cipla Limited Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
EP3650014B1 (fr) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
WO2015040640A2 (fr) * 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
EP2860185A1 (fr) 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables
IN2013CH05455A (fr) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
WO2015107451A2 (fr) 2014-01-14 2015-07-23 Mylan Laboratories Ltd. Purification de ténofovir alafénamide et de ses intermédiaires
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN105814068B (zh) * 2014-02-27 2017-08-04 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
CN105001262B (zh) * 2014-04-18 2017-09-01 四川海思科制药有限公司 芳基取代的磷酰胺类衍生物及其在医学上的应用
WO2015161781A1 (fr) * 2014-04-21 2015-10-29 四川海思科制药有限公司 Procédé pour la préparation d'un analogue de nucléoside et intermédiaire correspondant
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN105518012B (zh) * 2014-06-25 2018-03-02 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
KR101703257B1 (ko) 2014-09-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
WO2016052930A1 (fr) * 2014-09-30 2016-04-07 한미정밀화학주식회사 Procédé de préparation de (r)-9-[2-(phosphonométhoxy)propyl]adénine de grande pureté
EP3203995A4 (fr) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN108191913A (zh) * 2014-11-12 2018-06-22 四川海思科制药有限公司 一种替诺福韦艾拉酚胺晶型a及其制备方法
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
WO2016108205A1 (fr) 2015-01-03 2016-07-07 Mylan Laboratories Limited Procédés de préparation d'hémifumarate de ténofovir alafénamide amorphe et d'un prémélange de ce composé
US20180148774A1 (en) * 2015-05-16 2018-05-31 Godx, Inc Point of need testing device and methods of use thereof
CN106188139B (zh) * 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
JP2018524308A (ja) * 2015-06-17 2018-08-30 ギリアード サイエンシーズ， インコーポレイテッド テノホビルアラフェナミドの共結晶、塩および結晶形態
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MX386992B (es) 2015-08-10 2025-03-19 Merck Sharp & Dohme Llc Compuestos antivirales de fosfodiamida de éster de beta-aminoácido.
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
TWI616453B (zh) * 2015-08-27 2018-03-01 Substituted amino acid thioester compounds, compositions and uses thereof
WO2017037608A1 (fr) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Formes solides de ténofovir alafénamide et sels associés, procédés pour leur préparation et compositions pharmaceutiques associées
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
CN106866737B (zh) * 2015-12-11 2020-11-20 南京圣和药物研发有限公司 膦酸衍生物及其应用
EP3390413B1 (fr) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Composés oximes phosphoramides antiviraux
WO2017118928A1 (fr) 2016-01-06 2017-07-13 Lupin Limited Procédé servant à la séparation de diastéréomères de ténofovir alafénamide
PT3411378T (pt) 2016-02-02 2020-07-28 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107709288A (zh) * 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
WO2017148290A1 (fr) * 2016-03-01 2017-09-08 深圳市塔吉瑞生物医药有限公司 Composé d'adénine substituée et composition pharmaceutique correspondante
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
CZ2016156A3 (cs) 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017211325A1 (fr) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 Nouvelle forme cristalline de sel de ténofovir alafénamide, procédé de préparation et utilisation correspondante
CN107698621A (zh) * 2016-06-20 2018-02-16 杭州和泽医药科技有限公司 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
WO2017221189A1 (fr) * 2016-06-22 2017-12-28 Laurus Labs Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
CN106317116A (zh) * 2016-08-19 2017-01-11 张红利 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
SI3347352T1 (sl) 2016-08-19 2019-08-30 Gilead Sciences, Inc. Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
EP3503895B1 (fr) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir
CN106380484A (zh) * 2016-08-29 2017-02-08 杭州百诚医药科技股份有限公司 一种替诺福韦艾拉酚胺的新晶型及其制备方法
WO2018042331A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
WO2018051250A1 (fr) 2016-09-14 2018-03-22 Viiv Healthcare Company Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc
EP3532069A4 (fr) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. Composés aryl-amide phosphodiamide antiviraux
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
MA47094A (fr) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc Promédicaments d'ester aliphatique antiviral de ténofovir
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
WO2018115046A1 (fr) 2016-12-23 2018-06-28 Sandoz Ag Formes solides cristallines de ténofovir alafénamide
TWI868958B (zh) 2017-01-31 2025-01-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (fr) 2017-02-24 2018-08-30 Hexal Ag Composition stable de ténofovir alafénamide
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN106866739B (zh) * 2017-03-10 2018-11-02 华东师范大学 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP3600332B1 (fr) 2017-03-20 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Prophylaxie du vih post-exposition
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
KR102379965B1 (ko) * 2017-05-19 2022-03-29 주식회사 종근당 테노포비르의 효율적인 제조방법
CN107266499B (zh) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 一种抗病毒化合物及其制备方法
WO2019003251A1 (fr) 2017-06-30 2019-01-03 Cipla Limited Compositions pharmaceutiques
WO2019014247A1 (fr) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprenant un inhibiteur d'arn polymérase et de la cyclodextrine pour le traitement d'infections virales
WO2019021319A1 (fr) 2017-07-27 2019-01-31 Cipla Limited Compositions pharmaceutiques
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107655987B (zh) * 2017-09-08 2020-11-03 厦门蔚扬药业有限公司 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
WO2019084020A1 (fr) 2017-10-24 2019-05-02 Gilead Sciences, Inc. Méthodes de traitement de patients co-infectés par un virus et la tuberculose
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
WO2019130354A1 (fr) 2017-12-30 2019-07-04 Cipla Limited Formes polymorphes de (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)éthyl]amino]phénoxy phosphinyl]méthoxy]propyl]adénine et leurs sels pharmaceutiquement acceptables
CA3087932A1 (fr) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Composes acetal et leurs utilisations therapeutiques
KR102708995B1 (ko) * 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
EP3737359A4 (fr) * 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska Promédicaments antiviraux et formulations de ceux-ci
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CN108101943B (zh) * 2018-02-28 2020-11-24 顾世海 一种替诺福韦前药或可药用盐及其在医药上的应用
CA3132832A1 (fr) 2018-04-09 2019-10-17 Howard E. Gendelman Promedicaments antiviraux et formulations de ceux-ci
CA3103522C (fr) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Inhibiteurs de capsides pour le traitement du vih
WO2020018399A1 (fr) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Promédicaments d'amide phosphinique de ténofovir
JP7313438B2 (ja) 2018-09-19 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの予防のためのインテグラーゼ阻害剤
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021011891A1 (fr) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Formulations à action prolongée de ténofovir alafénamide
WO2021015818A1 (fr) 2019-07-19 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prophylaxie pré-exposition du vih
WO2021034804A1 (fr) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Formulations pharmaceutiques de ténofovir alafénamide
EP4017499A4 (fr) 2019-08-22 2024-01-10 Emory University Promédicaments nucléosidiques et leurs utilisations
US20220372171A1 (en) * 2019-09-20 2022-11-24 Abbott Rapid Diagnostics International Unlimited Company Antibody directed against tenofovir and derivatives thereof
TW202519228A (zh) 2019-11-26 2025-05-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
EP4085062A1 (fr) 2020-02-20 2022-11-09 Cipla Limited Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021202669A2 (fr) 2020-04-01 2021-10-07 Reyoung Corporation Composés conjugués de nucléoside et de nucléotide et leurs utilisations
EP4132651B1 (fr) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
EP4143199B1 (fr) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Composés de promédicaments nucléotidiques
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (fr) 2020-06-24 2023-05-03 Gilead Sciences, Inc. Analogues de 1'-cyano nucléoside et leurs utilisations
EP4172157B1 (fr) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de capside pour le traitement du vih
CN113970612B (zh) * 2020-07-22 2023-08-01 北京四环制药有限公司 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
CN112336695B (zh) * 2020-09-28 2023-01-03 华北制药华坤河北生物技术有限公司 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法
EP4660325A3 (fr) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Procédés d'identification de patients vih sensibles à une thérapie avec des anticorps dirigés contre le site de liaison de la gp120 cd4
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
CN113075307B (zh) * 2021-03-08 2025-03-11 瑞阳制药股份有限公司 富马酸丙酚替诺福韦异构体的检测方法
CN113214322B (zh) * 2021-04-30 2022-10-25 山东立新制药有限公司 替诺福韦绿色环保的制备方法
WO2022251594A1 (fr) * 2021-05-27 2022-12-01 Antios Therapeutics, Inc. Pharmacocinétique et améliorations liées à la dose chez des sujets traités avec des promédicaments de phosphoramidate de clevudine
WO2023102529A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composés thérapeutiques pour l'infection par le virus du vih
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
CN114369120A (zh) * 2022-01-28 2022-04-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦关键中间体的制备方法
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4680243A1 (fr) 2023-03-17 2026-01-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Méthodes de traitement de la dégénérescence maculaire liée à l'âge
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
WO2024249592A1 (fr) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Dérivés de quinazolinyl-indazole en tant que composés thérapeutiques pour le vih
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080850A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080879A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Composés antiviraux
WO2025184447A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'intégrase du vih
EP4640214A1 (fr) 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimé comprenant du monofumarate de ténofovir alafénamide
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN118652277A (zh) * 2024-08-19 2024-09-17 成都工业学院 一种用于治疗癌症疾病的化合物的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5053215A (en) * 1988-05-26 1991-10-01 University Of Florida NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
JP2648516B2 (ja) 1989-07-27 1997-09-03 ダイセル化学工業株式会社 立体異性体の分離法
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
JP2925753B2 (ja) 1990-02-23 1999-07-28 ダイセル化学工業株式会社 光学異性体の分離方法
EP0452935B1 (fr) * 1990-04-20 1995-06-21 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic (Phosphonométhoxy)-2-propyl-guanines chirales comme agents anti-viraux
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CS276072B6 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
DE69132276T2 (de) 1990-08-10 2001-03-01 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Verfahren zur herstellung von nukleotiden
DE69129650T2 (de) * 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
US5498752A (en) 1991-08-22 1996-03-12 Daicel Chemical Industries, Ltd. Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution
JP3010816B2 (ja) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法
JP3497505B2 (ja) 1991-10-11 2004-02-16 インスティテュート オブ オルガニック ケミストリー アンド バイオケミストリー オブ ザ アカデミー オブ サイエンシズ オブ ザ チェコ パブリック 抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
KR100386685B1 (ko) * 1993-09-17 2003-12-31 길리애드 사이언시즈, 인코포레이티드 뉴클레오타이드동족체류
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
WO1995007920A1 (fr) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Analogues de nucleotides
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
ATE245161T1 (de) * 1995-05-26 2003-08-15 Genta Inc Verfahren zur synthese von phosphororganischen verbindungen
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
NZ325704A (en) 1995-12-29 2000-02-28 Gilead Sciences Inc Nucleotide analogs
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
WO1998004569A1 (fr) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Analogues de nucleotides
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
NZ501659A (en) 1997-07-25 2004-12-24 Gilead Sciences Inc Methods of nucleotide analogue 9-[2[[bis[(pivaloyloxy)-methoxy]phosphinyljmethoxyjethyl] adenine ("adefovir dipivoxil" or "AD") synthesis
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
PT1243590E (pt) 1997-07-25 2005-05-31 Gilead Sciences Inc Composicao de analogos nuclotidicos e metodo de sintese
CA2312975C (fr) * 1997-12-17 2012-08-21 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6348185B1 (en) * 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6169879B1 (en) * 1998-09-16 2001-01-02 Webtv Networks, Inc. System and method of interconnecting and using components of home entertainment system
GB9821058D0 (en) † 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
ATE241633T1 (de) † 1999-02-12 2003-06-15 Glaxo Group Ltd Phosphoramidat-, mono-, di-, und triphosphatester von (1r, cis)-4-(6-amino-9h-purin-9-yl)-2- cyclopentene-1-methanol als antivirale mittel
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
US7034109B2 (en) * 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
US20020119433A1 (en) * 2000-12-15 2002-08-29 Callender Thomas J. Process and system for creating and administering interview or test

Also Published As

Publication number Publication date
KR20030022295A (ko) 2003-03-15
HUS000494I2 (hu) 2021-03-29
CN1443189A (zh) 2003-09-17
PL213214B1 (pl) 2013-01-31
EE200300029A (et) 2004-10-15
IS6689A (is) 2003-01-17
LTPA2016009I1 (lt) 2016-04-25
CN1706855A (zh) 2005-12-14
HU230960B1 (hu) 2019-06-28
BR0112646A (pt) 2003-06-24
CY1119411T1 (el) 2018-03-07
HRP20160074A8 (hr) 2016-07-29
CA2416757A1 (fr) 2002-01-31
IL153658A0 (en) 2003-07-06
ES2627903T3 (es) 2017-08-01
TR200300055T2 (tr) 2004-12-21
JP2011140506A (ja) 2011-07-21
NO20030270L (no) 2003-03-20
US20050159392A1 (en) 2005-07-21
AU2005225039A1 (en) 2005-11-10
JP2004504402A (ja) 2004-02-12
NO336718B1 (no) 2015-10-26
HRP20160074B1 (hr) 2021-09-03
HRP20160074A2 (hr) 2016-03-11
CY2016008I1 (el) 2016-12-14
NO20150909L (no) 2003-03-20
OA12393A (en) 2006-04-18
US20080227754A1 (en) 2008-09-18
KR100767432B1 (ko) 2007-10-17
BG107572A (bg) 2003-11-28
CY2016008I2 (el) 2016-12-14
NZ536942A (en) 2006-03-31
EP2682397A1 (fr) 2014-01-08
AP2003002724A0 (en) 2003-06-30
KR20060105807A (ko) 2006-10-11
FR16C0013I1 (fr) 2016-05-27
BRPI0112646B1 (pt) 2017-10-17
UA75889C2 (uk) 2006-06-15
SI1301519T1 (sl) 2015-07-31
NZ535408A (en) 2006-09-29
CA2725819A1 (fr) 2002-01-31
WO2002008241A2 (fr) 2002-01-31
US20020119443A1 (en) 2002-08-29
SI2682397T1 (sl) 2017-08-31
NZ523438A (en) 2005-02-25
CZ304734B6 (cs) 2014-09-10
IS2985B (is) 2017-09-15
NO20131717L (no) 2003-03-20
HRP20030047B1 (hr) 2016-02-26
EE05366B1 (et) 2010-12-15
EP3235823A1 (fr) 2017-10-25
CA2893174A1 (fr) 2002-01-31
HUP0301307A2 (hu) 2003-09-29
ES2536972T5 (es) 2022-04-06
HK1054238A1 (en) 2003-11-21
US20040018150A1 (en) 2004-01-29
AU2005225039B2 (en) 2008-09-25
EP2682397B1 (fr) 2017-04-19
EA200300188A1 (ru) 2003-06-26
NO20120466L (no) 2003-03-20
BRPI0112646B8 (pt) 2021-05-25
LT2682397T (lt) 2017-06-12
JP2010174033A (ja) 2010-08-12
HUP0301307A3 (en) 2005-12-28
DK1301519T4 (da) 2021-12-20
MXPA03000587A (es) 2004-04-05
ES2536972T3 (es) 2015-06-01
CN100402539C (zh) 2008-07-16
FR16C0013I2 (fr) 2016-09-09
US7390791B2 (en) 2008-06-24
US20050124583A1 (en) 2005-06-09
EP1301519B2 (fr) 2021-11-10
HUS1900027I1 (hu) 2021-03-29
AU2001282941B2 (en) 2006-04-27
DK1301519T3 (en) 2015-05-26
AP1466A (en) 2005-09-22
US20060024659A1 (en) 2006-02-02
EP1301519B1 (fr) 2015-02-25
JP5063554B2 (ja) 2012-10-31
US7803788B2 (en) 2010-09-28
NL300803I2 (fr) 2016-06-30
CN1291994C (zh) 2006-12-27
JP5111551B2 (ja) 2013-01-09
JP2009062383A (ja) 2009-03-26
US20050009043A1 (en) 2005-01-13
US20030219727A1 (en) 2003-11-27
EP1301519A2 (fr) 2003-04-16
NO2016006I1 (no) 2016-04-19
CA2416757C (fr) 2011-02-15
BE2016C018I2 (fr) 2020-08-20
CA2725819C (fr) 2015-09-22
NO2016006I2 (no) 2016-04-19
ZA200210271B (en) 2003-12-31
JP4651264B2 (ja) 2011-03-16
PL360490A1 (en) 2004-09-06
US20050124585A1 (en) 2005-06-09
HK1243711A1 (en) 2018-07-20
CZ304886B6 (cs) 2015-01-07
PT1301519E (pt) 2015-06-11
LTC1301519I2 (lt) 2023-02-27
WO2002008241A3 (fr) 2002-08-29
PT2682397T (pt) 2017-05-31
DK2682397T3 (da) 2017-06-19
US20050124584A1 (en) 2005-06-09
CZ2003413A3 (cs) 2003-12-17
NO2023006I1 (no) 2023-02-03
NO20030270D0 (no) 2003-01-20
AU8294101A (en) 2002-02-05
BG66037B1 (bg) 2010-11-30
EA004926B1 (ru) 2004-10-28
HRP20030047A2 (en) 2007-08-31
AU2001282941C1 (en) 2016-12-22
KR100749160B1 (ko) 2007-08-14

Similar Documents

Publication Publication Date Title
LU93029I2 (fr) Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir
ITTO20010902A0 (it) Macchina da caffe'.
JP2004512810A5 (fr)
JP2004504166A5 (fr)
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
MXPA03005743A (es) Antagonistas muscarinicos.
ZA200309136B (en) HGG formulation.
MXPA03008853A (es) Antagonistas de ccr5 utiles para el tratamiento del sida.
ITTO20000503A0 (it) Macchina per caffe'.
MXPA03008896A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos.
MXPA03001783A (es) N-(3,5-dicloro-2-metoxifenil)-4-metoxi-3- piperazin-1 -il -bencenosulfonamida.
ZA200205982B (en) Endoparasiticidal agents.
IT1318674B1 (it) Faramaci per l'incontinenza.
MXPA01011743A (es) Arilpirimidinas substituidas 5-.
ITRM20010098V0 (it) Macchina erogatrice di caffe'.
GB2360279B (en) I.S. Machine
ITRM990493A0 (it) Dispositivo di comando manuale, in particolare per l'accelerazione.
JP2003154400A5 (fr)
JP2003156591A5 (fr)
EP1266916A4 (fr) Copolymere multisequence et son procede de preparation
FI20030531A7 (fi) Teurastajan työkalu
GB0000470D0 (en) Templates
GB2379929B (en) I. S. machine
GB0007510D0 (en) D.o.t.t.s
JP2001336582A5 (fr)